Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05910684
Other study ID # Pro00060013
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 19, 2022
Est. completion date January 30, 2024

Study information

Verified date April 2024
Source Qure Healthcare, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a national-level research study of primary care physicians. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling, and others) of a subset of common patient care indications.


Description:

In the original study protocol (approved on October 19th, 2021), which the investigators are now referring to as Phase 1, the investigators measured changes in clinical practice using Clinical Performance and Value (CPVs) vignettes, described below. Phase 1 utilized simulated patients to determine clinical variation in the management of chronic cardiometabolic diseases and assessed the impact of the CDMT results on physicians' clinical decision-making. CPVs are QURE's scientifically-validated measurement tool, first described in JAMA, 2000, and now used in scores of scientific investigations. In this research and derivative peer-reviewed publications, QURE's CPV studies efficiently measure clinical practice patterns among active physicians to determine if there is value in new technologies to payers. This amendment allows us to ask the same physicians if they change their practice in an actual clinical setting. Phase 2 extends the findings from Phase 1 by measuring the change in clinical practice using CPVs and securing data on practice patterns from abstracted medical records. the investigators will look for the same changes the investigators found in Phase 1 to determine the impact of CDMT on real-world clinical decisions and patient outcomes. The advantage of Phase 2 is that it leverages the same sample frame and the randomization by returning to the physicians in Round 1 who indicated that CDMT would change their practice. These physicians will be given, free of charge, the option of using CDMT on their real patients who share similar medical diagnoses as the CPV simulated patients. Phase 2 will thus provide patient-level data on the impact of medication adherence assessment on quality outcomes including, but not limited to, blood pressure control, blood sugar control, and parameters of disease progression


Recruitment information / eligibility

Status Completed
Enrollment 114
Est. completion date January 30, 2024
Est. primary completion date January 30, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Board-certified physician currently practicing in either Family Medicine or Internal Medicine. - Have practiced as a board-certified physician in internal or family medicine or greater than 2 but less than 30 years - Community/non-academic based practice setting - = 40 patients under care weekly - Commonly treats patients with atrial fibrillation, coronary artery disease, congestive heart failure, diabetes, hypertension, and hyperlipidemia - Patient HIPAA Authorization form signed upon initial enrollment into the provider's practice - Practicing in the U.S. - English-speaking - Access to the internet - Informed and voluntarily consented to be in the study Exclusion Criteria: - Not a board-certified physician - Not practicing in the United States - Not informed and voluntarily consented to be in the study.

Study Design


Intervention

Diagnostic Test:
Aegis CDM Test and Educational Materials
The Aegis CDM diagnostic test will be given to intervention participants to use on their patients. The participants will receive the results of the test through a web portal. Investigators will analyze the differences in quality of care between the control arm and the intervention arm.

Locations

Country Name City State
United States QURE Healthcare San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Qure Healthcare, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Chart abstraction measured variation in quantity of care Measuring the difference in the quality of care between the control arm and the intervention arm as measured by the number of care decisions made in the second round of chart abstraction.
These care decisions might include decisions such as avoidance of invasive diagnostic tests, reductions in unneeded specialist referrals, increased diagnosis and treatment of drug-drug interactions, or care decisions related to costs.
[19 months]
Primary Chart abstraction measured variation in quality of care Measuring the difference in the quality of care between the control arm and the intervention arm as measured by the quality of care decisions made in the second round of chart abstraction.
These care decisions might include decisions such as avoidance of invasive diagnostic tests, reductions in unneeded specialist referrals, increased diagnosis and treatment of drug-drug interactions, or care decisions related to costs.
[19 months]
Primary Chart abstraction measured variation in clinical decisions Measuring the variation in amount of evidence based clinical decisions among practicing primary care physicians in the assessment, recognition, and adjustment of treatment due to medication non-adherence and DDIs in patients with chronic cardiometabolic diseases. [19 months]
See also
  Status Clinical Trial Phase
Recruiting NCT05880758 - Impact of Yo-Yo Sleep on Cardiometabolic Health N/A
Active, not recruiting NCT05192590 - Establishing Clinical Utility Evidence for Chronic Disease Management Testing N/A
Completed NCT06058845 - Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV N/A
Completed NCT05473026 - Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors N/A
Enrolling by invitation NCT06284772 - FINRISK 2002 Re-examination
Completed NCT05071833 - Effects of Peppermint Oil in Cardiometabolic Outcomes N/A
Active, not recruiting NCT05309057 - Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk
Recruiting NCT05897073 - Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity N/A
Recruiting NCT06371937 - iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease
Recruiting NCT06003686 - Spinal Cord Injury Model Systems (SCIMS) - Education Module N/A
Recruiting NCT05775016 - Effects of Adding L-BAIBA to Exercising Adult Overweight and Obese Men and Women N/A
Recruiting NCT05350111 - CArdioMetabolic Prevention in Adolescents N/A
Completed NCT06158191 - Long-term Benefits of Abdominal Fat Loss in Abdominally Obese Dyslipidemic Patients (SYNERGIE Study) N/A
Recruiting NCT04801745 - Vegan Diet, Amla Fruits and Uric Acid N/A
Not yet recruiting NCT06230861 - Effects of Quercetin on Cardiometabolic Outcomes N/A
Active, not recruiting NCT05627570 - A Study Comparing the Health Effects of Two Diets Following UK Dietary Guidance in People Living With Overweight or Obesity N/A
Active, not recruiting NCT04784624 - Virtual Lifestyle Program Evaluation During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Enrolling by invitation NCT05079529 - Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome Phase 2
Completed NCT04776629 - A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors Phase 2
Completed NCT06457711 - Blood Pressure and Cardiometabolic Risk (Diet-to-HTN) N/A